Mitochondrial Diseases Clinical Trial
Official title:
A Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 After a Single and Multiple Ascending Oral Doses in Healthy Subjects and Patients With Primary Mitochondrial Disease
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy volunteers only and will be completed before Part C including patients with primary mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will be 25 mg. The dose level in the additional cohorts will be decided following review of data of the previous cohorts.
Part A: Eight healthy subjects will be studied in a single cohort (Group A1). Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will participate in 2 treatment periods, fasting or after consuming a standard high-fat breakfast. For each treatment period, subjects will reside at the Phase I clinical site from Days 1 to 3 (48 hours postdose). Subjects will return to the clinical site for outpatient visits on Days 4 and 5. There will be at least a 10 day washout between doses Additional single-dose cohorts may be enrolled based on data obtained from either Parts A or B. Part B: Sixteen healthy subjects will be studied in 2 cohorts (Groups B1 and B2), with each cohort consisting of 8 subjects. Following review of safety, tolerability, and PK data, up to 3 additional dose cohorts of healthy subjects may be added to further explore the PK, safety, and tolerability of KL1333. Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. All subjects will participate in 1 treatment period and will reside at the Phase I clinical site from Days -1 to 12 (48 hours post final dose). Subjects will return to the clinical site for outpatient visits on Days 13 and 14. On Day 1, 6 subjects will be randomised to receive KL1333 and 2 subjects will be randomised to receive placebo. Subjects will return for a Follow-up visit on Day 15, 5 days after their final dose. Part C: A total of 8 patients diagnosed with any mitochondrial disease will be enrolled in this part of the study. Part C may start after the dose selection conference has been completed for the final cohort of Part B, at a daily dose no higher than the highest well-tolerated dose in Part B. Potential study patients will be screened to assess their eligibility to enter the study within 35 days prior to the first dose administration. Patients will reside at the clinical site from Days -1 to 2 and Days 10 to 11 and return to the clinical site for outpatient visits on Days 4 and 8. It is planned for patients to receive study drug once daily on Days 1 to 10. Patients will return for a Follow-up visit on Day 15, 5 days after their final dose. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03388528 -
Low Residue Diet Study in Mitochondrial Disease
|
N/A | |
Completed |
NCT04378075 -
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
|
Phase 2/Phase 3 | |
Completed |
NCT03678740 -
Diagnostic Odyssey Survey 2
|
||
Recruiting |
NCT06051448 -
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
|
Phase 1/Phase 2 | |
Completed |
NCT02909400 -
The KHENERGY Study
|
Phase 2 | |
Completed |
NCT02398201 -
A Study of Bezafibrate in Mitochondrial Myopathy
|
Phase 2 | |
Completed |
NCT03857880 -
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip
|
||
Not yet recruiting |
NCT06450964 -
Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases
|
||
Completed |
NCT04165239 -
The KHENERGYZE Study
|
Phase 2 | |
Completed |
NCT02284334 -
Glycemic Index in Mitochondrial Disease
|
||
Recruiting |
NCT06080581 -
Mitochondrial Dysfunctions Driving Insulin Resistance
|
||
Recruiting |
NCT06080568 -
Human Mitochondrial Stress-driven Obesity Resistance
|
||
Recruiting |
NCT04802707 -
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
|
Phase 2 | |
Completed |
NCT04580979 -
Natural History Study of FDXR Mutation-related Mitochondriopathy
|
||
Completed |
NCT04594590 -
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
|
||
Withdrawn |
NCT03866954 -
Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy
|
Phase 2 | |
Recruiting |
NCT04113447 -
Mitochondrial Donation: An 18 Month Outcome Study.
|
||
Enrolling by invitation |
NCT04734626 -
CrCest Study in Primary Mitochondrial Disease
|
||
Completed |
NCT03832218 -
Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies
|
N/A | |
Terminated |
NCT02473445 -
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
|
Phase 2 |